C5 Recombinant Monoclonal Antibody

Code: CSB-RA003995MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P01031

Target Names

Alternative Names

Anaphylatoxin C5a analog antibody; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 antibody; C5 antibody; C5a anaphylatoxin antibody; C5a antibody; C5b antibody; CO5_HUMAN antibody; Complement C5 alpha'' chain antibody; Complement C5 antibody; Complement component C5 antibody; CPAMD4 antibody; prepro-C5 antibody

Species Reactivity

Human

Immunogen

Recombinant Human C5 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Mouse IgG

Clone No.

13H2

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
FC	1:20-1:500

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

Overlay Peak curve showing Hela cells surface stained with CSB-RA003995MA1HU (red line) at 1:800. Then 10% normal goat serum was Incubated to block non-specific protein-protein interactions followed by the antibody (1µg/1*10⁶cells) for 45 min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/200 dilution for 35 min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1µg/1*10⁶cells) used under the same conditions. Acquisition of >10, 021 events was performed.

Description

Complement component C5 occupies a pivotal position in the complement cascade, serving as the molecular switch between the inflammatory and membrane attack phases of innate immunity. Upon cleavage by C5 convertases, C5 generates the potent anaphylatoxin C5a, which drives neutrophil chemotaxis and inflammatory signaling, alongside C5b, which initiates assembly of the membrane attack complex. This dual functionality makes C5 a compelling target for researchers investigating complement-mediated inflammation, autoimmune pathology, and therapeutic intervention strategies in conditions ranging from paroxysmal nocturnal hemoglobinuria to neurodegenerative disease.

This recombinant monoclonal antibody, clone 13H2, offers the reproducibility and molecular definition that complement research demands. Developed using recombinant technology with a defined mouse IgG2a framework, it delivers the lot-to-lot consistency essential for longitudinal studies and quantitative assays where subtle variations in antibody performance could compromise data interpretation. The antibody was raised against recombinant human C5 protein and demonstrates validated reactivity with human samples.

Flow cytometry validation confirms reliable surface detection of C5 on HeLa cells, with effective staining demonstrated at dilutions from 1:20 to 1:500, providing flexibility to optimize signal-to-noise ratios across different experimental contexts. The antibody is additionally validated for ELISA applications, supporting both cell-based and biochemical approaches to C5 quantification.

Supplied in a glycerol-stabilized PBS formulation ready for immediate use, this antibody serves immunology researchers exploring complement biology, inflammatory mechanisms, and the growing field of complement-targeted therapeutics.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.; Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Gene References into Functions

these data demonstrate that Mesenchymal Stem Cells inhibit the activation of pathogenic C5 via up-regulation of FH, which improves our understanding of the immunomodulatory mechanisms of MSCs in the treatment of lupus nephritis. PMID:29885865
recombinant C5a potentiated TNFalpha-induced NF-kappaB activation in renal tubular epithelial cells PMID:29031143
tumoral C5a is an independent adverse prognostic biomarker for clinical outcome of Clear Cell Renal Cell Carcinoma patients after nephectomy. PMID:27381421
C5a synergises with P. aeruginosa LPS in both PD-L1 expression and the production of IL-10 and TGF-beta. PMID:27624143
these results not only confirm the critical role of C5b-9 in complement-mediated hemolysis and but also highlight the critical role of C5b-9 in inflammasome activation. PMID:27444648
Mean cerebrospinal fluid C5 levels increased in patients with depression and schizophrenia. PMID:29454970
elevated in the cerebrospinal fluid of preterm newborns PMID:27806664
Up-regulation of granulocyte and monocyte CD11b during plasma separation was C5-dependent. PMID:29575196
This study provides the preclinical rationale for the combined blockade of PD-1/PD-L1 and C5a to restore antitumor immune responses, inhibit tumor cell growth, and improve outcomes of patients with lung cancer PMID:28288993
Diagnosis and therapeutic management of neonatal hemochromatosis cannot only be based on C5b9 expression in liver samples as it is not specific of this disease. PMID:28085791
C5a-C5aR enriched clear cell renal cell carcinoma patients significantly had a poorer overall survival and recurrence free survival after nephrectomy. PMID:27821813
C5a/C5aR pathway promotes gastric cancer pathogenesis by suppressing p21/p-p21 expression via activation of PI3K/AKT signaling. PMID:29031586
this study shows that C5 acts in the control of serum triglycerides and cholesterol, liver cholesterol deposition, liver homeostasis and C5 promotes a pro-inflammatory liver environment in our mouse model of alcoholic liver disease PMID:26896155
a library of 61 peptides based on the C-terminus of C5a was assayed for the ability to selectively modulate C5aR2 function. PMID:27108698
Data show the expression of a neoepitope which was exposed on complement C5 (C5) after binding to eculizumab in vivo. PMID:28610663
Plasma levels of sC5b-9 were significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation. PMID:28801815
C5 gene analysis revealed two novel mutations as causative of C5 deficiency in 3 north African families PMID:27026170
data indicate that properdin enhances platelet/granulocyte aggregates (PGAs) formation via increased production of C5a, and that inhibition of properdin function has therapeutic potential to limit thromboinflammation in diseases characterized by increased PGA formation PMID:27183616
this study shows that complement C5a-induced changes in neutrophil morphology during inflammation PMID:28671713
Increased C5a expression is associated with increased inflammation in cystic fibrosis. PMID:28278205
Our results provide evidence that an intrinsic C5a generation may not be fully blocked by eculizumab in various disease settings. Controlling and fully blocking C5a induced signaling in humans therefore warrants a targeted approach PMID:28366510
These findings, together with data from genomic variation databases, indicate a 0.5-2% prevalence of the Complement factor 5 (C5) p.A252T mutation in heterozygosity in sub-Saharan Africa. Therefore, this mutation may have a relevant role in meningococcal disease susceptibility in this geographical area. PMID:28369827
we found the GG variant contributing to the risk of LAA-subtype ischemic stroke but were unable to find an association between ischemic stroke functional outcome at 90 days and C5 rs17611 variants. PMID:27901252
this study shows that C5a signaling induces apoptosis in brain vascular endothelial cells in experimental lupus PMID:27213693
We determined the genotypes of five polymorphisms (rs12237774, rs17611, rs4837805, rs7026551, and rs1017119) of C5 gene. In univariate analysis, rs17611 was significantly associated with Ischemic Stroke (IS) in the additive model, the dominant model, and recessive model. In this sample of patients, genetic variation of rs17611 in C5 is associated with higher prevalence of IS. PMID:27768391
the complement anaphylatoxin C5a shows an inverse correlation with platelet bound oxLDL. The relationship of oxidized lipids to particular complement components may add to the platelet-lipid interplay in atherogenesis and trigger future clinical and mechanistic studies. PMID:27025272
In an arterial thrombosis model, plasminogen activator administration increased C5a levels. Overall, these findings suggest plasmin bridges thrombosis and the immune response by liberating C5a and inducing MAC assembly. PMID:27077125
C5 rs2269067 GG genotype confers risk for proliferative diabetic retinopathy of type 2 diabetes in Chinese Han population (associated with an elevated C5 mRNA expression and an increased IL-6 production) PMID:26934706
C5a can induce the expression of TLR4 in retinal pigment epithelial cells. PMID:26487798
elevated in the inflammatory lesions of placentas with villitis of unknown etiology PMID:25725937
These results identify complement activation product C5a as a priming signal for RPE cells that allows for subsequent inflammasome activation by stimuli such as lipofuscin-mediated photooxidative damage. PMID:26565031
a significant up-regulation (173 fold increase, p < 0.0001) in the expression of inflammatory complement component 5 (C5) in endometriosis was detected for the first time. PMID:24316322
Complement C5b-9 complex sensitizes 661W photoreceptor cells to both apoptosis and necroptosis. PMID:25735751
complement C5a signaling supports human stem cell pluripotency and survival, and thus may play a key role in shaping early human embryonic development PMID:25132103
Rs2900180 in C5-TRAF1 and linked variants in a 66Kb region were associated with radiographic progression in ACPA-negative RA PMID:25566937
The C5 rs2269067 GG genotype confers risk for AAU in a Chinese population and is associated with an elevated C5 serum concentration and an increased IL-17 production. PMID:26230759
TRAF1/C5 rs10818488 polymorphism is not a genetic risk factor for acquired aplastic anemia in a Chinese population. PMID:25500258
This study shows that individuals homozygously expressing the rheumatoid arthritis risk s17611 allele exhibit increased C5a and decreased C5 in plasma, evidence of increased C5 turnover. PMID:25725109
Elevated sC5b-9 levels are indicative of active disease in atypical hemolytic uremic syndrome. PMID:25818678
In conclusion, the present study indicates that C5a may promote the proliferation of breast cancer cells through Akt1 activation of the RGC-32 gene. PMID:25230890
C5A is released from C5 by a cancer cell membrane bound serine protease which enchances neoplasm invasiveness, immune evasion, and neovascularization. PMID:25050844
The interaction between S1P and C5a plays an important role in neutrophils for antineutrophil cytoplasmic antibody -mediated activation PMID:25000985
Our data provide new insights into the regulatory role of C5a in PMN function during systemic C. albicans infection in human blood and identify C5a as an essential mediator of PMN activation in response to C. albicans. PMID:25539819
This report includes seven affected families indicating that C5 deficiency is not rare in South Africa. PMID:25534848
This study reveals that the C5 complement protein may play a critical role in mediating white matter injury through inflammation in the setting of chronic cerebral hypoperfusion. PMID:24386419
the role of C5a as an endogenous priming signal that is required for the initiation of uric acid crystal-induced IL-1beta production. PMID:25229885
Spontaneous abortion is associated with elevated systemic C5a and reduced mRNA of complement inhibitory proteins in placenta. PMID:24802103
C5a, but not C5a-des Arg, was able to induce further heteromer formation between complement C5a receptors. PMID:24060963
Data indicate that cholesterol crystals (CC) employed C5a in the release of IL-1beta. PMID:24554772
Serum level of initiating complement factor (C1q) but not complement regulator C5 is deficient in schizophrenic patients. PMID:23235303